Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00889642
Recruitment Status : Completed
First Posted : April 29, 2009
Last Update Posted : June 23, 2009
Information provided by:
Dharma Therapeutics Inc.

Brief Summary:
The purpose of this study is to evaluate the effectiveness of administering Lidocaine and Epinephrine using an iontophoretic device treatment to provide local anesthesia to healthy adult volunteer subjects undergoing venipuncture.

Condition or disease Intervention/treatment Phase
Local Anesthesia Device: Iontophoretic Drug Delivery System with Lidocaine/Epinephrine Device: Iontophoretic Drug Delivery System with Epinephrine Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter Double-Blind Randomized Placebo Controlled Two-Arm Study Evaluating the Safety and Efficacy of the Iontophoretic Administration of Lidocaine and Epinephrine Using Lidocaine Iontophoretic Drug Delivery System (IDDS) to Provide Local Anesthesia for Venipuncture in Healthy Adult Volunteer Subjects
Study Start Date : May 2009
Actual Primary Completion Date : May 2009
Actual Study Completion Date : June 2009

Arm Intervention/treatment
Active Comparator: Active
Contains Lidocaine and Epinephrine
Device: Iontophoretic Drug Delivery System with Lidocaine/Epinephrine
Active- 10.5% Lidocaine/0.179% Epinephrine
Placebo Comparator: Placebo
Contains Epinephrine
Device: Iontophoretic Drug Delivery System with Epinephrine
Placebo- 0.179% Epinephrine

Primary Outcome Measures :
  1. Following the iontophoresis treatment an IV will be inserted into the treatment area and the amount of pain will be assessed using the median visual analog pain scale (VAS). [ Time Frame: 4 hours ]
  2. Monitor the nature and frequency of adverse events associated with the iontophoretic device through observation during treatment. [ Time Frame: 4 hours ]

Secondary Outcome Measures :
  1. Determining the duration of anesthesia through standard pin prick testing. [ Time Frame: 4 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects may be of any race, either sex, and must be >18 years of age
  • Healthy subjects as per medical screening
  • Subjects must have intact, healthy skin (no tattoos, surgical scars, skin infections, etc.) where the iontophoresis treatment will be performed
  • Subjects must be alert, oriented, mentally competent, and able to understand and comply with the requirements of the study
  • Subjects must have signed and dated a written informed consent
  • Female subjects of childbearing potential must have a negative pregnancy test result prior to the iontophoresis treatment

Exclusion Criteria:

  • Subjects with a known allergy or sensitivity to lidocaine, epinephrine or other local anesthetics of the amide or ester type
  • Subjects with a know sensitivity to any components (e.g. adhesives) of the IDDSSubjects who have undergone venipuncture in the treatment area within the prior 2 weeks or longer if bruising or hematoma is apparent
  • Subjects who have taken an analgesic pain medication during the 24-hour period prior to the venipuncture in the posterior surface of the hand
  • Subjects with skin allergies or have skin diseases (e.g. psoriasis, eczema
  • Subjects with an open skin lesion at the treatment site
  • Subjects who are pregnant or breastfeeding
  • Subjects exposed to an investigational drug or device within the past 30 days or are involved concurrently in other treatment clinical trials
  • Subjects who participated in previous DTI/Transcu clinical studies related to this product
  • Subjects with known concurrent illness
  • Subjects with "current" known/admitted substance abuse (alcohol/drug)
  • Subjects with pacemakers and/or externally mounted electronic devices
  • Current or history of conditions that contraindicate use of iontophoretic treatment or venipuncture

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00889642

United States, California
Advanced Clinical Research Institute
Anaheim, California, United States, 92801
United States, Missouri
Vince & Associates Clinical Research
Overland Park, Missouri, United States, 66212
Sponsors and Collaborators
Dharma Therapeutics Inc.

Responsible Party: Ron Berenson, Acting Medical Director, Dharma Therapeutics Inc. Identifier: NCT00889642     History of Changes
Other Study ID Numbers: Dharma-NSCO3
First Posted: April 29, 2009    Key Record Dates
Last Update Posted: June 23, 2009
Last Verified: June 2009

Additional relevant MeSH terms:
Epinephryl borate
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents